Helport AI Advances Transition to Autonomous AI Labor in Southeast Asian Fintech Market C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel…
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
Fast Track designation granted by the U.S. Food and Drug Administration (FDA) to Wee1 Inhibitor,…
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults…
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
NEW HAVEN, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a…
Gritstone to Participate in Cowen 42nd Annual Health Care Conference
EMERYVILLE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage…
Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM,…
BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)
— Analysis from APeX-2 showed 94 percent attack-free days across all patients who completed 96…
Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
PITTSBURGH, Feb. 24, 2022 (GLOBE NEWSWIRE) — Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader…
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
WAYNE, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage…
Amicus Therapeutics Announces Full-Year 2021 Financial Results and Corporate Updates
Galafold® Revenue Growth of 17% YoY to $306M in 2021 Galafold Global Sales Growing at Double-Digits…
Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
Completed dose escalation in the KT-474 SAD and MAD portions of Phase 1 trial, with…
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
Pluristem officially closed a deal with Israel’s largest food brand Tnuva on February 24 2022,…
Immuneering Announces Participation in March Investor Conferences
Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling…
Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022
WOODCLIFF LAKE, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (“Eagle” or the…
SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights
– Topline Analysis from Phase 3 DeFi Trial Expected to be Triggered in the First Quarter…
Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H…
Notice to Convene the Annual General Meeting of Genmab A/S
Company Announcement Genmab A/S to hold Annual General Meeting on Tuesday March 29, 2022 COPENHAGEN,…
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2021 Financial Results
SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
Clover Selected for Inclusion on the Hang Seng Composite Index
CHENGDU, China, Feb. 24, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a…
Striim Introduces Striim Cloud, the First Unified Real-Time Data Streaming and Integration SaaS
Striim Cloud is the fastest way for customers to deliver real-time data to power next…